logo
How Can Europe Reduce Heat Deaths Amid Rising Temperatures?

How Can Europe Reduce Heat Deaths Amid Rising Temperatures?

Medscape12 hours ago
The Pan-European Commission on Climate and Health has released an open letter urging action against the escalating health crisis in Europe and Central Asia that is stemming from climate change.
Europe is the fastest-warming region in the world, warming up twice as fast as the global average. While 2024 was the hottest year on record for continental Europe, 2025 is already on its way to surpassing it. T emperatures rose above 30 ˚C for an unprecedented 22 days in Scandinavia, while Spain and Portugal experienced heat exceeding 46 ˚C in June.
Such temperature rises have had a deleterious impact on health; data show that heat-related mortality has increased by more than 30% in the last two decades in Europe. This trend is showing no signs of slowing down. An analysis by Imperial College London , London, England, reported that 1500 of the 2300 heat deaths in the week between June 23 and July 2, 2025, were a direct result of climate change-related temperature rises of 1-4 °C.
Excess heat can exacerbate underlying health issues like c ardiovascular disease, diabetes, mental health conditions, and asthma , and increase the risk for accidents and the transmission of some infectious diseases. Older people, young children, and pregnant women are at particular risk.
'In the summer of 2022, 60,000-70,000 [people] died in Europe because of heat,' Julie Berckmans, PhD, European Environment Agency (EEA) climate risk and adaptation expert, told Medscape Medical News . 'In 2023, it was 47,000 people. These numbers could increase substantially in the coming decades. To avoid this, effective actions have to be implemented to protect vulnerable people.'
A man cools off at a fountain in St.Peter's Square at the Vatican on August 13, 2025. Italy faced extreme heat in August as temperatures above 40 °C gripped the country.
Heat-Health Actions Plans (HHAPs)
In their letter, the Pan-European Commission on Climate and Health highlighted the need for HHAPs to save lives and prevent further climate decline.
HHAPs provide a framework for reducing the health impacts of extreme heat. They focus on eight core elements: a governing structure for heat-health action, warning systems, care for vulnerable populations, heat-health communications planning, health system resilience, reduced heat exposure, surveillance, and a process for review and improvement, Vladimir Kendrovski, MD, PhD, World Health Organization (WHO)/Europe technical officer for climate change and health, told Medscape Medical News .
At present, 21 of the 38 countries belonging to the EEA network, Eionet, have HHAPs in place. While this is encouraging, said Kendrovski, accelerating their development and implementation across Europe remains a 'critical priority.'
Many countries began to implement HHAPs in response to the 2003 heatwave — the hottest period in continental Europe since at least 1540, claiming more than 70,000 lives. France and Italy , for example, saw significant declines in heat-related deaths after implementing preventative measures like warning system s, information campaigns for the public , and a ir conditioning equipment and emergency protocols for health centers and retirement homes.
Some measures, however, are more widespread than others. Kendrovski noted that a survey of member states in the region found that long-term urban planning and real-time surveillance, monitoring, and evaluation are still lacking.
Andreas Hoy, PhD, senior expert and climate scientist at the Stockholm Environment Institute Tallinn, in Tallinn, Estonia, noted that the technical components of early meteorological warning systems have been significantly updated in recent years, thus enabling better warning systems. However, he added, an absence of formal standards has led to wide variations in HHAP structures, objectives, and execution.
'This inconsistency often produces fragmented efforts and leaves major gaps in funding, vulnerability assessments, and long-term resilience planning,' he said.
Lateral Public Health
While improved infrastructure is important, community engagement is key toward ensuring it is used properly to ultimately reduce deaths, Jan Semenza, PhD, project manager at the Department of Epidemiology and Global Health at Umeå University, Umeå, Sweden, told Medscape Medical News .
Toward this end, he recommends a 'lateral' as opposed to 'vertical' approach to public health : rather than eliminating one health threat at a time, such as polio through vaccination campaigns, lateral approaches enhance community cohesion for a more self-organized and thus agile collective response to disasters, including heatwaves.
Measures may include community-based surveillance, health education, and projects like establishing urban gardens to cool air through transpiration or painting roofs green to reduce rooftop temperatures.
'One thing we found from our research in Chicago,' said Semenza, 'is that people who have social connections, participate in church communities, or even have a pet that allows you to go outside and connect with people — these are the ones that are more likely to survive. If you're isolated, nobody looks after you.'
Semenza added that urban planning should also be taken into account and recommended the creation of more green spaces to offset heating from cement and concrete.
More Solutions
Hoy noted that while long-term solutions aimed at reducing greenhouse gas emissions to prevent further heating are necessary, public awareness campaigns are still needed in the short-term to help people stay safe during heatwaves.
'Providing clear and simple guidance on how to stay safe during a heatwave can save lives: such as staying hydrated, seeking shade, and looking out for elderly neighbors, friends, and family members,' he told Medscape Medical News .
In terms of immediate solutions, Ilona M. Otto, PhD, deputy director at the Wegener Center for Climate and Global Change at the University of Graz, Graz, Austria, recommends using public spaces and buildings, such as libraries, as cooling centers, in addition to providing access to drinking stations, improved insulation, and assistance to vulnerable people living alone.
Regulations for working conditions may also need to be adjusted, she said, to ensure that those working in difficult conditions can take more breaks, have more access to water, and perhaps stop working at the hottest times of the day.
Healthcare professionals also have a key role in implementing HHAPs, Rachel Lowe, PhD, Catalan Institution for Research and Advanced Studies Research Professor at the Barcelona Supercomputing Center, told Medscape Medical News.
'Health professionals can detect and treat heat-sensitive and climate-related illnesses early and educate patients on prevention. They also play a key role in public awareness, surveillance, and advocating for greener, more resilient health systems that can withstand climate pressures and reduce the carbon footprint of the health sector,' she said.
The WHO Regional Office for Europe is currently developing new guidance for HHAPs, which is expected to be published in Spring 2026.
Berckmans, Kendrovski, Lowe, and Semenza reported no relevant financial relationships. Otto noted that a part of her work has been carried out within the HIGH Horizons project , funded by the European Union's Horizon Research and Innovation programme. Their project partner, London School of Hygiene & Tropical Medicine, is funded by UK Research & Innovation. Hoy declined to disclose any relevant financial relationships.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pricey Drugs Unlikely to Solve Dementia
Pricey Drugs Unlikely to Solve Dementia

Medscape

time4 hours ago

  • Medscape

Pricey Drugs Unlikely to Solve Dementia

This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease. Biomarkers and Lifestyle We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology . A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. Just to give you an example, there is one study from the US published in Neurology with more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. Herpes Zoster and Cognitive Impairment There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated relative risk reduction for dementia was 20%. Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%. GLP-1 Drugs and Anti-Amyloids We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists. Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities. At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies. With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. Spend Money on Lifestyle At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle. I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on. Dear colleagues, this is a short update on what has happened recently in the field of dementia. I'm Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.

BioEcho Unveils EchoLUTION™ Cell Culture RNA Kit, Delivering Superior Quality and Speed for Research
BioEcho Unveils EchoLUTION™ Cell Culture RNA Kit, Delivering Superior Quality and Speed for Research

Associated Press

time6 hours ago

  • Associated Press

BioEcho Unveils EchoLUTION™ Cell Culture RNA Kit, Delivering Superior Quality and Speed for Research

BioEcho launches new EchoLUTION™ Cell Culture RNA kit, offering superior quality and speed for academic and biopharma research in under 10 minutes. COLOGNE, GERMANY, August 21, 2025 / / -- BioEcho Life Sciences GmbH, an Admera Health company, has launched its new EchoLUTION™ Cell Culture RNA purification kit. This kit utilizes the revolutionary one-step EchoLUTION™ technology to deliver superior RNA quality with high recovery rates and more usable reads in downstream applications. The purification method drastically reduces hands-on time and overall turnaround, with a workflow of under 10 minutes. The launch of the Cell Culture RNA kit follows the successful introduction of the EchoLUTION™ FFPE RNA kit in late 2023. Both kits are critical tools for academic and biopharma researchers, offering significant cost savings by eliminating multiple wash steps and reducing the use of consumables. The new kit is available in 96- and 384-well plate formats and can be used with a variety of sample types. This new approach inverts the logic of traditional purification, which has for decades relied on harsh, inefficient binding techniques. By retaining impurities and allowing the nucleic acids to pass through in a single step, the method eliminates multiple wash steps, which are a major source of sample loss and time consumption. 'We are proud to introduce a product that will significantly improve the efficiency and quality of nucleic acid purification workflows,' said Dr. Sarah Eckenrode, General Manager of BioEcho. 'The EchoLUTION™ Cell Culture RNA kit is a game-changer for academic and biopharma researchers who need fast, reliable, and cost-effective solutions. We developed this kit to address the common bottlenecks associated with traditional methods, providing a gentle yet powerful alternative that truly reveals the unseen.' The new EchoLUTION™ Cell Culture RNA kit is a critical tool for researchers in academic and biopharma labs. It is available in 96- and 384-well plate formats and can be used with a variety of sample types. About BioEcho Life Sciences GmbH BioEcho Life Sciences is an ISO 9001 certified company specializing in nucleic acid sample preparation tools for life sciences research, agricultural, and industrial applications. Founded in 2016 by a team of industry experts in genomic sample preparation, BioEcho was established with the mission of utilizing its proprietary technologies and technical expertise to overcome the limitations of many standardized methods in molecular biology workflows. BioEcho kits offer customers industry-leading quality, speed, simplicity, and sustainability for the purification of high-quality nucleic acids from a wide variety of samples. Our mission is to provide simple, safe, and sustainable solutions that enable our customers to reveal the unseen and echoing true biology. For more information, visit Sarah Eckenrode BioEcho Life Sciences [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Dr. Nikola Cihoric Redefines Clinical Research Through Innovation, Technology, and Data
Dr. Nikola Cihoric Redefines Clinical Research Through Innovation, Technology, and Data

Associated Press

time7 hours ago

  • Associated Press

Dr. Nikola Cihoric Redefines Clinical Research Through Innovation, Technology, and Data

ZURICH, SWITZERLAND, August 21, 2025 / / -- Bridging Medicine, Research, and Technology for Patient-Centric Solutions Dr. Nikola Cihoric, founder and visionary behind Wemedoo AG, is redefining clinical research by merging technology, innovation, medicine, and data into a seamless ecosystem that empowers healthcare professionals and researchers alike. With over 15 years of experience in radiation oncology and a deep commitment to clinical data standardization, Dr. Cihoric is setting a new standard in the way clinical trials are conducted worldwide. A Vision Born from Real Clinical Challenges Wemedoo was born from Dr. Cihoric's firsthand frustration with fragmented healthcare systems and inefficient clinical workflows. 'I observed the paper world and sloppy digitalization that slowed treatment delivery and overburdened medical staff,' he explains. His focus on data standardization and cross-sector collaboration led to the development of an early prototype, oopus (initially SmartOncology), which received support from the Swiss Cancer Foundation. Building on this experience, Wemedoo developed its unique approach, which eliminates silos, enhances transparency, and gives researchers full control across the clinical data lifecycle. Learn more about Dr. Cihoric's vision in the Xraised interview. Transforming Clinical Trials Through Technology Unlike traditional clinical trial solutions that rely on multiple disconnected systems, Wemedoo's oomnia system integrates EDC, CTMS, eTMF, eConsent, RTSM, and advanced reporting in a single, unified, and interoperable environment. This approach eliminates costly integrations, reduces errors, and ensures data consistency across every stage of a trial. 'By using technology to unify processes, we save time, reduce errors, and provide real-time insights for clinicians and researchers,' Dr. Cihoric notes. 'Our no-code configuration also allows rapid adaptation to evolving trial requirements, ensuring flexibility without compromising quality.' Ethical AI and Data-Driven Innovation Wemedoo integrates AI into oomnia practically and responsibly, focusing on automating processes where it delivers immediate value without unnecessary risks, essential in a highly regulated industry. Their work is guided by explainability and transparency, from AI-driven risk assessment tools for protocol design to semantic mapping engines that cut data processing timelines from months to days. Wemedoo is also exploring agentic AI to support operational decision-making, always with a 'man-in-control' philosophy to ensure accountability. What makes this possible is oomnia's semantic foundation, structured data, common data elements, and standard vocabularies, which keep outcomes reproducible, interpretable, and aligned with regulatory frameworks. Beyond technology, Wemedoo collaborates with public institutions and publish in peer-reviewed journals, reinforcing their belief that AI is only meaningful if it strengthens trust, transparency, and data integrity. Balancing Clinical Practice and Product Development Despite his active role at Wemedoo, Dr. Cihoric continues to work in a leading academic hospital. This dual role allows him to translate real-world clinical challenges into actionable system improvements. 'Being close to patients and clinical teams keeps me grounded in reality, ensuring that our technology delivers tangible benefits,' he says. Long-Term Vision for Clinical Research Looking ahead, Dr. Cihoric aims to remove barriers between clinical practice and research, investing in education, resources, and stakeholder alignment to ultimately improve patient outcomes. 'The goal is to create a future where innovation, technology, and real-world data converge seamlessly to benefit patients worldwide,' he asserts. About Dr. Nikola Cihoric Dr. Nikola Cihoric is a radiation oncologist, researcher, and founder of Wemedoo AG, with expertise in clinical data standardization, AI integration, and oncology innovation. He has published over 35 scientific papers and actively contributed to international standards groups such as mCODE, CodeX, HL7/FHIR, and CDISC. For more information on Dr. Nikola Cihoric and Wemedoo's groundbreaking work, visit Wemedoo and explore insights from Xraised ( ). Media and Business Inquiries General contact: [email protected] Business development: [email protected] Website: LinkedIn: Wemedoo AG. Gianmarco Giordaniello Xraised email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store